The five components of an Investigational New Drug (IND) application include: (1) preclinical testing to assess the compound’s safety, (2) disclosure of manufacturing information, (3) investigator information that discloses the investigator’s qualifications, (4) clinical trial protocols, and (5) commitments that include informed consent, institutional review board (IRB) evaluation, and compliance with investigational new drug regulations.